undamentalytics Newsletter
Sign in

Axogen, Inc. income statement

In fiscal 2025, Axogen, Inc. reported revenue of $225m, up 20.2% on the year before, operating income of −$7.8m (a -3.5% margin) and net income of −$15.7m, or −$0.34 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2010Dec 20102011Dec 20112012Dec 20122013Dec 20132014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMSept 2026
Revenue358111727416084107112127139159187225267
Cost of revenue——————69131722233037455869
Gross profit226913223551718991104109122142167198
Research and development01123347121818242627283337
Selling and marketing34710132028385772707372787898117
General and administrative3456781015233126324138394557
Operating income−4−7−8−10−10−9−8−8−21−31−23−25−30−21−3−8−14
Interest expense11157452101113882
Income before tax—−9−10−15—————————————
Income tax——−100000000000000
Net income−5−9−9−15−18−13−14−10−22−29−24−27−29−22−10−16−32
Diluted EPS−$8.35−$2.77−$0.85−$1.08−$0.99−$0.51−$0.47−$0.31−$0.60−$0.74−$0.60−$0.65−$0.69−$0.51−$0.23−$0.34−$0.61
Diluted shares (average)——11m13m18m26m31m33m37m39m40m41m42m43m44m46m52m
EBITDA−4−7−8−10−10−9−8−7−20−30−22−23−27−173−1−7

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: AXGN vs KIDSAXGN vs LMATAXGN vs CERSAXGN vs SKIN

More: Health Care Equipment stocks compared, Health Care sector, rankings of US companies

Figures from Axogen, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Axogen, Inc.